Compounds > amlodipine, atorvastatin drug combination
Page last updated: 2024-11-12

amlodipine, atorvastatin drug combination

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11982821
MeSH IDM0548292

Synonyms (5)

Synonym
amlodipine, atorvastatin drug combination
amlodipine/atorvastatin
930274-47-8
DTXSID101009852
calcium;benzenesulfonic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate;(3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"7%) patients due to adverse events."( EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA.
Georgieva Torbova-Gigova, S; Ivanov Manov, E; Margaritov Runev, N; Naydenov Naydenov, S, 2018)		0.48

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets."( Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.
Curran, MP, 2010)		0.36

Dosage Studied

ExcerptRelevanceReference
" The combination of amlodipine and atorvastatin in 8 different dosage strengths were flexibly titrated over a period of 14 weeks."( Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin.
Cheung, BM; Lam, KS; Li, M; Tse, HF; Xu, A, 2011)		0.37
"BACKGROUND Is the timing of dosing for amlodipine and atorvastatin important with regard to therapeutic efficacy? To answer this question, we designed an outpatient, practice-based, case-control study lasting 8 weeks."( Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?
Wang, M; Zeng, R; Zhang, L, 2016)		0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (21.21)29.6817
2010's24 (72.73)24.3611
2020's2 (6.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.30 (24.57)
Research Supply Index3.91 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index45.90 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (40.00%)5.53%
Reviews6 (17.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (42.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-center, Randomized, Parallel Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension [NCT03860220]Phase 4304 participants (Anticipated)Interventional2019-03-01Not yet recruiting
Effect of Caduet and TLC Intervention on Metabolic Parameters [NCT03504735]Phase 453 participants (Actual)Interventional2005-05-01Completed
Open Label, Comparative, Multiple-dose, Fixed-sequence Steady State Trial in Healthy Volunteers to Assess the Pharmacokinetic Interaction of Ramipril, Atorvastatin and Amlodipine After a Multiple Oral Dose Administration [NCT04262765]Phase 118 participants (Actual)Interventional2019-02-23Completed
Caduet® Drug Use Investigation (Regulatory Post Marketing Commitment Plan) [NCT01107743]1,291 participants (Actual)Observational2010-06-30Completed
A Multi-Center, Open Label Study To Evaluate Long Term Safety Of Caduet In Patient With Both Of Hypertension And Hypercholesterolemia, Or With Both Of Angina Pectoris And Hypercholesterolemia [NCT01190007]Phase 4159 participants (Actual)Interventional2010-08-31Completed
Evaluation of Carotid Intima Media Thickness by Treatment of Vascular and Metabolic Factors With Combined Antihypertensive and Hypolipidemic Therapy [NCT04306627]Phase 4200 participants (Anticipated)Interventional2020-04-15Not yet recruiting
Clinical Utility Of Caduet In Simultaneously Achieving Blood Pressure And Lipid Endpoints In A Specific Patient Population (CAPABLE) [NCT00150384]Phase 4500 participants Interventional2004-07-31Completed
An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial Examining The Efficacy And Safety Of Caduet® In Simultaneously Achieving Blood Pressure And Lipid Goals In An Untreated Hypertensive And Dyslipidemic Subject Population. (CUSP - Caduet in Untrea [NCT00332761]Phase 4220 participants Interventional2006-06-30Completed
Clinical Utility of Amlodipine/Atorvastatin to Improve Concomitant Cardiovascular Risk Factors of Hypertension and Dyslipidemia [NCT00143234]Phase 31,825 participants Interventional2004-05-31Completed
An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL Study) [NCT00330785]Phase 31,250 participants Interventional2004-10-31Completed
Randomized, Multicenter, Parallel, Open, Phase 4 Study to Compare the Efficacy and Safety of Rosuvastatin/Amlodipine Combination Therapy Versus Atorvastatin/Amlodipine Combination Therapy in Hypertension Patient With Dyslipidemia [NCT03951207]Phase 4259 participants (Actual)Interventional2019-05-30Completed
Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation (IMPRESSION) [NCT04111419]Phase 41,200 participants (Anticipated)Interventional2020-07-01Recruiting
An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study) [NCT00174304]Phase 41,120 participants Interventional2004-10-31Completed
Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension [NCT05165251]Phase 4480 participants (Anticipated)Interventional2022-01-04Recruiting
An Experimental Study on the Effect of Tenofovir Amibufenamide on Blood Lipid During Anti-HBV Treatment [NCT05398393]150 participants (Anticipated)Interventional2022-01-01Enrolling by invitation
An Open-label, Randomized, Two-sequence, Multiple-dose, Crossover Study to Evaluate Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers [NCT03461081]Phase 132 participants (Actual)Interventional2017-05-07Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01107743 (38) [back to overview]Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Angina Pectoris.
NCT01107743 (38) [back to overview]Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Hypercholesterolemia or Familial Hypercholesterolemia.
NCT01107743 (38) [back to overview]Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Hypertension.
NCT01107743 (38) [back to overview]Number of Treatment Related Adverse Events.
NCT01107743 (38) [back to overview]Risk Factor for the Proportion of Responders of Amlodipine/Atorvastatin Combination Tablets for Hypercholesterolemia or Familial Hypercholesterolemia - Hypercholesterolemia Expression Type.
NCT01107743 (38) [back to overview]Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Age.
NCT01107743 (38) [back to overview]Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Angina Pectoris.
NCT01107743 (38) [back to overview]Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Complications.
NCT01107743 (38) [back to overview]Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Concomitant Drugs.
NCT01107743 (38) [back to overview]Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Familial Hypercholesterolemia.
NCT01107743 (38) [back to overview]Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Gender.
NCT01107743 (38) [back to overview]Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hepatic Dysfunction.
NCT01107743 (38) [back to overview]Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia Expression Type.
NCT01107743 (38) [back to overview]Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia.
NCT01107743 (38) [back to overview]Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension Severity.
NCT01107743 (38) [back to overview]Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension.
NCT01107743 (38) [back to overview]Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Renal Dysfunction.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Angina Pectoris -Age.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Angina Pectoris -Angina Pectoris Severity.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Angina Pectoris -Complications.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Angina Pectoris -Concomitant Drugs.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Angina Pectoris -Gender.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Angina Pectoris -Hepatic Dysfunction.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Angina Pectoris -Renal Dysfunction.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Age.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Complications.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Concomitant Drugs.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Gender.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Hepatic Dysfunction.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Renal Dysfunction.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypertension -Age.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypertension -Complications.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypertension -Concomitant Drugs.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypertension -Gender.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypertension -Hepatic Dysfunction.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypertension -Hypertension Severity.
NCT01107743 (38) [back to overview]Risk Factors for the Proportion of Responders for Hypertension -Renal Dysfunction.
NCT01107743 (38) [back to overview]Number of Treatment Related Unlisted Adverse Events in Japanese Package Insert.
NCT01190007 (12) [back to overview]Change From Baseline in Ratio of Low Density Lipoprotein Cholesterol (LDL-C) to High Density Lipoprotein Cholesterol (HDL-C) at Each Visit
NCT01190007 (12) [back to overview]Change From Baseline in Ratio of Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Each Visit
NCT01190007 (12) [back to overview]Change From Baseline in Trough Diastolic Blood Pressure (DBP) at Each Visit in Participant Population With Angina Pectoris and Hypercholesterolemia
NCT01190007 (12) [back to overview]Change From Baseline in Trough Diastolic Blood Pressure (DBP) at Each Visit in Participant Population With Both Hypertension and Hypercholesterolemia
NCT01190007 (12) [back to overview]Change From Baseline in Trough Systolic Blood Pressure (SBP) at Each Visit in Participant Population With Both Hypertension and Hypercholesterolemia
NCT01190007 (12) [back to overview]Change From Baseline in Trough Systolic Blood Pressure (SBP) at Each Visit in Population With Both Angina Pectoris and Hypercholesterolemia
NCT01190007 (12) [back to overview]Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01190007 (12) [back to overview]Percent Change From Baseline in Apolipoprotein B at Each Visit
NCT01190007 (12) [back to overview]Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Each Visit
NCT01190007 (12) [back to overview]Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Each Visit
NCT01190007 (12) [back to overview]Percent Change From Baseline in Total Cholesterol (TC) at Each Visit
NCT01190007 (12) [back to overview]Percent Change From Baseline in Triglyceride (TG) at Each Visit

Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Angina Pectoris.

The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and enteterd the results for Angina Pectoris. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Amlodipine and Atorvastatin Combination Tablet163

[back to top]

Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Hypercholesterolemia or Familial Hypercholesterolemia.

The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results for Hypercholesterolemia or Familial Hypercholesterolemia. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Amlodipine and Atorvastatin Combination Tablet1034

[back to top]

Number of Participants That Responded to Amlodipine/Atorvastatin Treatment With Hypertension.

The physician performed efficacy evaluations at the end of the observation period (or the time of discontinuing administration), compared with the data before the start of administration of this drug, and entered the results for Hypertension. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Amlodipine and Atorvastatin Combination Tablet1151

[back to top] [back to top]

Risk Factor for the Proportion of Responders of Amlodipine/Atorvastatin Combination Tablets for Hypercholesterolemia or Familial Hypercholesterolemia - Hypercholesterolemia Expression Type.

"Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether Hypercholesterolemia expression type, Ⅰ, Ⅱa, Ⅱb, Ⅲ, Ⅳ, or Ⅴ is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia. Hypercholesterolemia expression types are defined by Japan Atherosclerosis Society Guideline for Prevention of Atherosclerosis Cardiovascular Diseases." (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Type Ⅰ13
Type Ⅱa533
Type Ⅱb180
Type Ⅲ10
Type Ⅳ5

[back to top]

Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Age.

Number of participants with Treatment Related Adverse Events (TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether <65 years or >=65 years is significant risk factor. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
<65 Years5
>=65 Years13

[back to top]

Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Angina Pectoris.

Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Angina pectoris is significant risk factor. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Angina Pectoris18
With Angina Pectoris0

[back to top]

Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Complications.

Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Complications is significant risk factor. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Complications5
With Complications13

[back to top]

Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Concomitant Drugs.

Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether Concomitant Drugs is significant risk factor. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Concomitant Drugs3
With Concomitant Drugs15

[back to top]

Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Familial Hypercholesterolemia.

Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Familial Hypercholesterolemia is significant risk factor. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Familial Hypercholesterolemia18
With Familial Hypercholesterolemia0

[back to top]

Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Gender.

Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether male or female is significant risk factor. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Male7
Female11

[back to top]

Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hepatic Dysfunction.

Number of participants with Treatment Related Adverse Events (TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hepatic Dysfunction is significant risk factor. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Hepatic Dysfunction14
With Hepatic Dysfunction2

[back to top]

Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia Expression Type.

"Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether Hypercholesterolemia expression type, Ⅰ, Ⅱa, Ⅱb, Ⅲ, Ⅳ, or Ⅴ is significant risk factor. Hypercholesterolemia expression types are defined by Japan Atherosclerosis Society Guideline for Prevention of Atherosclerosis Cardiovascular Diseases." (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Type Ⅰ0
Type Ⅱa10
Type Ⅱb2
Type Ⅲ0
Type Ⅳ0

[back to top]

Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia.

Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hypercholesterolemia is significant risk factor. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Hypercholesterolemia0
With Hypercholesterolemia18

[back to top]

Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension Severity.

"Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether Hypertension severity, ClassⅠ, ClassⅡ, or ClassⅢ is significant risk factor. Hypertension severity is defined by Guideline for the Management of hypertension (The Japan Society of Hypertension)." (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
ClassⅠ5
ClassⅡ4
ClassⅢ3

[back to top]

Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension.

Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hypertension is significant risk factor. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Hypertension0
With Hypertension18

[back to top]

Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Renal Dysfunction.

Number of participants with Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Renal Dysfunction14
With Renal Dysfunction2

[back to top]

Risk Factors for the Proportion of Responders for Angina Pectoris -Age.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether <65 years or >=65 is significant risk factor for Angina Pectoris. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
<65 Years45
>=65 Years118

[back to top]

Risk Factors for the Proportion of Responders for Angina Pectoris -Angina Pectoris Severity.

"Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether Angina Pectoris functional classification Severity, Class1, Class2, Class3, or Class4 is significant risk factor for Angina Pectoris. Angina Pectoris functional classification Severity is defined by Canadian Cardiovascular Society functional Classification of Angina." (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Class1122
Class211
Class32
Class41

[back to top]

Risk Factors for the Proportion of Responders for Angina Pectoris -Complications.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Angina Pectoris is significant risk factor for Angina Pectoris. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Complications57
With Complications106

[back to top]

Risk Factors for the Proportion of Responders for Angina Pectoris -Concomitant Drugs.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Concomitant Drugs is significant risk factor for Angina Pectoris. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Concomitant Drugs22
With Concomitant Drugs141

[back to top]

Risk Factors for the Proportion of Responders for Angina Pectoris -Gender.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether male or female is significant risk factor for Angina Pectoris. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Male75
Female88

[back to top]

Risk Factors for the Proportion of Responders for Angina Pectoris -Hepatic Dysfunction.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hepatic Dysfunction is significant risk factor for Angina Pectoris. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Hepatic Dysfunction145
With Hepatic Dysfunction18

[back to top]

Risk Factors for the Proportion of Responders for Angina Pectoris -Renal Dysfunction.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor for Angina Pectoris. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Renal Dysfunction137
With Renal Dysfunction25

[back to top]

Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Age.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether <65 years or >=65 is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
<65 Years305
>=65 Years729

[back to top]

Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Complications.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Complications is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Complications482
With Complications552

[back to top]

Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Concomitant Drugs.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Concomitant Drugs is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Concomitant Drugs306
With Concomitant Drugs728

[back to top]

Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Gender.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether male or female is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Male380
Female654

[back to top]

Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Hepatic Dysfunction.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hepatic Dysfunction is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Hepatic Dysfunction904
With Hepatic Dysfunction122

[back to top]

Risk Factors for the Proportion of Responders for Hypercholesterolemia or Familial Hypercholesterolemia -Renal Dysfunction.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor for Hypercholesterolemia or Familial Hypercholesterolemia. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Renal Dysfunction937
With Renal Dysfunction88

[back to top]

Risk Factors for the Proportion of Responders for Hypertension -Age.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether <65 years or >=65 is significant risk factor for Hypertension. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
<65 Years347
>=65 Years804

[back to top]

Risk Factors for the Proportion of Responders for Hypertension -Complications.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Complications is significant risk factor for Hypertension. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Complications527
With Complications624

[back to top]

Risk Factors for the Proportion of Responders for Hypertension -Concomitant Drugs.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Concomitant Drugs is significant risk factor for Hypertension. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Concomitant Drugs339
With Concomitant Drugs812

[back to top]

Risk Factors for the Proportion of Responders for Hypertension -Gender.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether male or female is significant risk factor for Hypertension. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Male415
Female736

[back to top]

Risk Factors for the Proportion of Responders for Hypertension -Hepatic Dysfunction.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Hepatic Dysfunction is significant risk factor for Hypertension. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Hepatic Dysfunction1008
With Hepatic Dysfunction131

[back to top]

Risk Factors for the Proportion of Responders for Hypertension -Hypertension Severity.

"Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether Hypertension severity, ClassⅠ, ClassⅡ, or ClassⅢ is significant risk factor for Hypertension. Hypertension severity is defined by Guideline for the Management of hypertension (The Japan Society of Hypertension)." (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
ClassⅠ615
ClassⅡ325
ClassⅢ85

[back to top]

Risk Factors for the Proportion of Responders for Hypertension -Renal Dysfunction.

Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor for Hypertension. (NCT01107743)
Timeframe: 8 weeks

Interventionparticipants (Number)
Without Renal Dysfunction1036
With Renal Dysfunction102

[back to top] [back to top]

Change From Baseline in Ratio of Low Density Lipoprotein Cholesterol (LDL-C) to High Density Lipoprotein Cholesterol (HDL-C) at Each Visit

Value at each visits minus value at baseline (NCT01190007)
Timeframe: Weeks 4, 12, 24, and 52

InterventionRatio (Mean)
Week 4 (n=157)Week 12 (n=155)Week 24 (n=151)Week 52 (n=144)Week 52 (LOCF) (n=156)
Caduet-0.4-0.3-0.3-0.4-0.4

[back to top]

Change From Baseline in Ratio of Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Each Visit

Value at each visits minus value at baseline (NCT01190007)
Timeframe: Weeks 4, 12, 24, and 52

InterventionRatio (Mean)
Week 4 (n=157)Week 12 (n=156)Week 24 (n=151)Week 52 (n=145)Week 52 (LOCF) (n=157)
Caduet-0.4-0.4-0.3-0.4-0.4

[back to top]

Change From Baseline in Trough Diastolic Blood Pressure (DBP) at Each Visit in Participant Population With Angina Pectoris and Hypercholesterolemia

Value at each visits minus value at baseline (NCT01190007)
Timeframe: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

InterventionmmHg (Mean)
Week 2 (n=15)Week 4 (n=16)Week 8 (n=16)Week 12 (n=16)Week 16 (n=16)Week 20 (n=16)Week 24 (n=16)Week 28 (n=16)Week 32 (n=16)Week 36 (n=15)Week 40 (n=15)Week 44 (n=15)Week 48 (n=15)Week 52 (n=15)Week 52 (LOCF) (n=16)
Caduet0.8-1.1-1.0-1.1-2.2-0.9-3.5-3.0-4.8-2.5-1.2-2.6-0.7-4.4-3.2

[back to top]

Change From Baseline in Trough Diastolic Blood Pressure (DBP) at Each Visit in Participant Population With Both Hypertension and Hypercholesterolemia

Value at each visits minus value at baseline (NCT01190007)
Timeframe: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

InterventionmmHg (Mean)
Week 2 (n=140)Week 4 (n=139)Week 8 (n=140)Week 12 (n=140)Week 16 (n=138)Week 20 (n=136)Week 24 (n=134)Week 28 (n=132)Week 32 (n=132)Week 36 (n=132)Week 40 (n=132)Week 44 (n=130)Week 48 (n=130)Week 52 (n=129)Week 52 (LOCF) (n=142)
Caduet0.3-0.40.2-0.2-0.7-1.8-1.6-2.6-3.5-4.3-3.2-2.5-2.0-0.6-0.6

[back to top]

Change From Baseline in Trough Systolic Blood Pressure (SBP) at Each Visit in Participant Population With Both Hypertension and Hypercholesterolemia

Value at each visits minus value at baseline (NCT01190007)
Timeframe: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

InterventionmmHg (Mean)
Week 2 (n=140)Week 4 (n=139)Week 8 (n=140)Week 12 (n=140)Week 16 (n=138)Week 20 (n=136)Week 24 (n=134)Week 28 (n=132)Week 32 (n=132)Week 36 (n=132)Week 40 (n=132)Week 44 (n=130)Week 48 (n=130)Week 52 (n=129)Week 52 (LOCF) (n=142)
Caduet-0.2-0.60.0-0.4-1.5-2.8-1.8-3.1-4.8-4.8-4.4-4.0-2.3-1.5-1.5

[back to top]

Change From Baseline in Trough Systolic Blood Pressure (SBP) at Each Visit in Population With Both Angina Pectoris and Hypercholesterolemia

Value at each visits minus value at baseline (NCT01190007)
Timeframe: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

InterventionmmHg (Mean)
Week 2 (n=15)Week 4 (n=16)Week 8 (n=16)Week 12 (n=16)Week 16 (n=16)Week 20 (n=16)Week 24 (n=16)Week 28 (n=16)Week 32 (n=16)Week 36 (n=15)Week 40 (n=15)Week 44 (n=15)Week 48 (n=15)Week 52 (n=15)Week 52 (LOCF) (n=16)
Caduet-1.1-2.3-1.1-2.2-2.3-2.3-6.7-6.8-7.8-5.7-2.7-3.7-0.4-4.4-3.1

[back to top]

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. (NCT01190007)
Timeframe: 52 weeks

InterventionParticipants (Number)
AESAE
Caduet12011

[back to top]

Percent Change From Baseline in Apolipoprotein B at Each Visit

"Value at each visits minus value at baseline divided by value at baseline multiplied by 100" (NCT01190007)
Timeframe: Week 4, 12, 24, and 52

InterventionPercentage of Apolipoprotein B (Mean)
Week 4 (n=157)Week 12 (n=156)Week 24 (n=151)Week 52 (n=145)Week 52 (LOCF) (n=157)
Caduet-9.2-5.8-7.4-9.1-9.3

[back to top]

Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Each Visit

"Value at each visits minus value at baseline divided by value at baseline multiplied by 100" (NCT01190007)
Timeframe: Weeks 4, 12, 24, and 52

InterventionPercentage of HDL-C (Mean)
Week 4 (n=157)Week 12 (n=156)Week 24 (n=151)Week 52 (n=145)Week 52 (LOCF) (n=157)
Caduet1.54.0-0.52.22.5

[back to top]

Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Each Visit

"Value at each visits minus value at baseline divided by value at baseline multiplied by 100" (NCT01190007)
Timeframe: Weeks 4, 12, 24, and 52

InterventionPercentage of LDL-C (Mean)
Week 4 (n=157)Week 12 (n=155)Week 24 (n=151)Week 52 (n=144)Week 52 (LOCF) (n=156)
Caduet-10.9-7.4-10.5-12.3-12.2

[back to top]

Percent Change From Baseline in Total Cholesterol (TC) at Each Visit

"Value at each visits minus value at baseline divided by value at baseline multiplied by 100" (NCT01190007)
Timeframe: Weeks 4, 12, 24, and 52

InterventionPercentage of TC (Mean)
Week 4 (n=157)Week 12 (n=156)Week 24 (n=151)Week 52 (n=145)Week 52 (LOCF) (n=157)
Caduet-7.3-5.0-7.9-8.0-8.1

[back to top]

Percent Change From Baseline in Triglyceride (TG) at Each Visit

"Value at each visits minus value at baseline divided by value at baseline multiplied by 100" (NCT01190007)
Timeframe: Week 4, 12, 24, and 52

InterventionPercentage of TG (Mean)
Week 4 (n=157)Week 12 (n=156)Week 24 (n=151)Week 52 (n=145)Week 52 (LOCF) (n=157)
Caduet8.23.66.48.57.2

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hydrochloric acid
Hydrochloric Acid: A strong corrosive acid that is commonly used as a laboratory reagent. It is formed by dissolving hydrogen chloride in water. GASTRIC ACID is the hydrochloric acid component of GASTRIC JUICE.. hydrogen chloride : A mononuclear parent hydride consisting of covalently bonded hydrogen and chlorine atoms.		2.1310chlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride		mouse metabolite
amlodipine
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.		13.533314dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
memantine
[no description available]		3.1210adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
spironolactone
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.		3.12103-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
diethylamine
[no description available]		2.1310secondary aliphatic amine
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		13.533314pyrrole;
secondary amine
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		3.1210mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
pravastatin
Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.		3.47113-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
atorvastatin
[no description available]		9.21125aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
duloxetine hydrochloride
Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.. (S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration.		3.1210duloxetine hydrochlorideantidepressant
eplerenone
Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.		3.12103-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester		aldosterone antagonist;
antihypertensive agent
telaprevir
[no description available]		3.4511cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
tiotropium bromide
Tiotropium Bromide: A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.. tiotropium bromide : An organic bromide salt having (1alpha,2beta,4beta,5alpha,7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane as the counterion. Used (in the form of the hydrate) for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.		3.1210
ru 66647
telithromycin: a ketolide; semisynthetic derivative of erythromycin with cycling of the C11-12 positions to form a carbamate ring to avoid acquired resistance to macrolides; binds 70S bacterial rRNA, specifically to the 23S part (23S RIBOSOMAL RNA), preventing protein synthesis;		3.1210
rifamycins
[no description available]		3.1210
cardiovascular agents
Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.		3.1210
ConditionIndicatedRelationship StrengthStudiesTrials
Cardiometabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.		03.6411
Metabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.		03.6411
Elevated Cholesterol
[description not available]		02.8330
Blood Pressure, High
[description not available]		011.84198
Hypercholesterolemia
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.		02.8330
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		011.84198
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		03.8921
Dyslipidemia
[description not available]		08.0562
Dyslipidemias
Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.		08.0562
Coronary Heart Disease
[description not available]		05.9933
Coronary Disease
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.		05.9933
Atherogenesis
[description not available]		02.0810
Fatty Liver, Nonalcoholic
[description not available]		02.0810
Liver Steatosis
[description not available]		02.0810
Diseases, Metabolic
[description not available]		02.0810
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		08.6574
Fatty Liver
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.		02.0810
Metabolic Diseases
Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)		02.0810
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		02.0810
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		02.0810
Chronic Kidney Diseases
[description not available]		04.411
Renal Artery Stenosis
[description not available]		04.411
Renal Artery Obstruction
Narrowing or occlusion of the RENAL ARTERY or arteries. It is due usually to ATHEROSCLEROSIS; FIBROMUSCULAR DYSPLASIA; THROMBOSIS; EMBOLISM, or external pressure. The reduced renal perfusion can lead to renovascular hypertension (HYPERTENSION, RENOVASCULAR).		04.411
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)		04.411
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		05.8222
Disease Exacerbation
[description not available]		03.511
Atheroma
[description not available]		03.511
Arteriosclerosis, Coronary
[description not available]		04.4322
Coronary Artery Disease
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.		04.4322
Chronic Illness
[description not available]		04.3611
Angina Pectoris, Stable
[description not available]		04.3611
Hyperlipemia
[description not available]		06.9152
Heart Disease, Ischemic
[description not available]		04.3611
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		04.3611
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		06.9152
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		04.3611
Angina, Stable
Persistent and reproducible chest discomfort usually precipitated by a physical exertion that dissipates upon cessation of such an activity. The symptoms are manifestations of MYOCARDIAL ISCHEMIA.		04.3611
Complications of Diabetes Mellitus
[description not available]		04.3711
Angor Pectoris
[description not available]		02.0210
Angina Pectoris
The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.		02.0210
Bone Loss, Perimenopausal
[description not available]		02.9410
Osteoporosis, Postmenopausal
Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.		02.9410
Cardiac Diseases
[description not available]		03.3520
Heart Diseases
Pathological conditions involving the HEART including its structural and functional abnormalities.		03.3520